GSK invests up to $800 million in Pennsylvania site, largest manufacturing investment in U.S.

• GSK is outfitting its Marietta, Pennsylvania, site with new state-of-the-art facilities dedicated to producing medicines and vaccines  
• The new R&D and commercial facilities will double the size and capacity of the site, creating over 200 new jobs in the region  
• This investment underscores GSK’s commitment to advancing science, technology and sustainability

GSK plc (LSE/NYSE: GSK) today announced its largest U.S. manufacturing investment to date. The up to $800 million investment will bring state-of-the-art drug substance manufacturing and additional drug product manufacturing capabilities to the company’s site in Marietta, Pennsylvania, along with over 200 new jobs. 

The new multi-purpose facility will be capable of manufacturing sterile liquid vaccines and medicines for which there is ever-increasing demand. This facility will also house a state-of-the-art R&D pilot plant to manufacture medicines for clinical trials. Additionally, GSK will establish a new vaccines drug substance facility at the site, dedicated to manufacturing products based on the company’s novel MAPS technology, subsequent to future regulatory submissions and approvals. This expansion will double the size and capacity of the Marietta site. 

Regis Simard, President Global Supply Chain, GSK, said: This landmark investment will establish Marietta as an innovation and manufacturing hub capable of delivering next generation medicines and vaccines to people around the world. We’re grateful for the support of local and state officials, who made this project possible, and we are excited to expand upon the important work already underway at the Marietta site.  

Pennsylvania Governor Josh Shapiro said: Pennsylvania is a leader in life sciences – and GSK’s decision to make its largest single investment ever in manufacturing in the United States right here in the Commonwealth is further proof that we are the best state in the nation for business growth and economic development. Our Commonwealth offers the skilled workforce, market access, and innovation infrastructure that biotech and life sciences companies need to thrive. Pennsylvania is getting things done, and my Administration will continue to work with companies like GSK to drive innovation forward and create jobs – and economic opportunity – for people across the Commonwealth.

Advancing GSK’s commitment to sustainability, the new drug product building at the Marietta site will be certified LEED Silver and will incorporate the latest technologies for solar panels, electric heat generation, and water and energy reclamation. Both facilities will feature smart utility and electrical system monitoring and controls, digital twins for continuous process optimization, robotics for material handling, and predictive maintenance and digital scheduling enabled by artificial intelligence. 

Construction of the new facilities is expected to start by the end of this year. The drug substance facility is anticipated to be operational by the end of 2027, with the drug product facility following by the end of 2028. 

Since 2017, GSK has invested close to $1.3 billion in U.S. manufacturing capabilities. 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

About GSK’s Marietta site 

With a heritage dating back to 1882, Marietta was GSK’s first site to continuously operate in the United States. Packing approximately 100 million doses annually for the US market and supplying 88 countries, Marietta is a critical link in the global GSK supply chain. Each year, one in four Americans are administered a vaccine issued from Marietta. This expansion will double the size and capacity of the site. 

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D “Risk factors” in GSK’s Annual Report on Form 20-F for 2023, and GSK’s Q2 Results for 2024.